Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Trial in 3 Parts Assessing the Safety, Tolerability, and Efficacy of a Once-daily Peanut Sublingual Immunotherapy (SLIT) Tablet in Adults, Adolescents, and Children With Peanut Allergy

NCT05440643 is registered in ClinicalTrials.gov with ALK-Abelló A/S as lead sponsor.

NCT NCT05440643
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05440643 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Trial in 3 Parts Assessing the Safety, Tolerability, and Efficacy of a Once-daily Peanut Sublingual Immunotherapy (SLIT) Tablet in Adults, Adolescents, and Children With Peanut Allergy
Lead sponsor
ALK-Abelló A/S
Phase
Phase 1/2
Overall status
Completed
Start date
September 7, 2022
Completion date
April 5, 2026
Enrollment
209 (actual)
Sites
42

Conditions

As the registry lists them; a condition with its own page is linked.

peanut allergy